These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Becker RH; Frick AD; Nosek L; Heinemann L; Rave K Diabetes Care; 2007 Oct; 30(10):2506-7. PubMed ID: 17675541 [No Abstract] [Full Text] [Related]
4. [Current insulin therapy. Treatment with new short-acting and retard insulin analogs]. Matthaei S; Hamann A Fortschr Med; 1997 Apr; 115(12):35-6, 39. PubMed ID: 9235301 [TBL] [Abstract][Full Text] [Related]
5. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Johansson UB; Amsberg S; Hannerz L; Wredling R; Adamson U; Arnqvist HJ; Lins PE Diabetes Care; 2005 Aug; 28(8):2025-7. PubMed ID: 16043749 [No Abstract] [Full Text] [Related]
6. [Taking the peak out of blood pressure. Diabetics can also live spontaneously]. MMW Fortschr Med; 1999 Dec; 141(49-50):66-7. PubMed ID: 10726151 [No Abstract] [Full Text] [Related]
7. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Raslova K Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842 [TBL] [Abstract][Full Text] [Related]
8. [Clinical effects and pharmacodynamics of insulin analogs lispro, aspart and glargin]. Heinemann L; Heise T Dtsch Med Wochenschr; 2001 May; 126(20):597-604. PubMed ID: 11402927 [No Abstract] [Full Text] [Related]
9. Limitations to subcutaneous insulin administration in type 1 diabetes. Chen JW; Christiansen JS; Lauritzen T Diabetes Obes Metab; 2003 Jul; 5(4):223-33. PubMed ID: 12795655 [No Abstract] [Full Text] [Related]
10. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Lepore G; Dodesini AR; Nosari I; Trevisan R Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625 [No Abstract] [Full Text] [Related]
12. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus. Kabadi UM Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012 [TBL] [Abstract][Full Text] [Related]
14. [Insulin treatment of type 1 diabetes in adults]. Birkeland KI Tidsskr Nor Laegeforen; 2006 Mar; 126(6):776-8. PubMed ID: 16541173 [No Abstract] [Full Text] [Related]
15. Insulin therapy during Ramadan fast for patients with type 1 diabetes mellitus. Azar ST; Khairallah WG; Merheb MT; Zantout MS; Fliti F J Med Liban; 2008; 56(1):46. PubMed ID: 19534091 [No Abstract] [Full Text] [Related]
16. A new experience for incorrect insulin administration. Kirac CO; Ipekci SH; Kebapcilar L Acta Diabetol; 2018 Sep; 55(9):985-986. PubMed ID: 29934655 [No Abstract] [Full Text] [Related]
17. [When tablets are no longer enough. Which insulin for type 2 diabetic patients?]. MMW Fortschr Med; 2002 Sep; 144(38):58. PubMed ID: 12395711 [No Abstract] [Full Text] [Related]
18. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Albright ES; Desmond R; Bell DS Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268 [No Abstract] [Full Text] [Related]
19. [Insulin therapy in patients with type 2 diabetes]. Siegmund T; Schumm-Draeger PM MMW Fortschr Med; 2008 May; 150(18):32-5; quiz 36. PubMed ID: 18533606 [No Abstract] [Full Text] [Related]